Track Johnson & Johnson — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Johnson & Johnson JNJ Open Johnson & Johnson in new tab

228.92 USD
P/E
26.24
EPS
8.64
Yield
2.29%
Safety Score
74
P/B
6.72
ROE
26.42
Beta
0.26
Target Price
252.96 USD
Johnson & Johnson logo

Johnson & Johnson

🧾 Earnings Recap – Q1 2026

Johnson & Johnson delivered a robust Q1 2026 with 6.4% operational sales growth, driven by strong performances across its innovative pharma and MedTech segments, and raised full-year guidance toward $100 billion revenue.

  • Q1 revenue grew 6.4% annually, with Innovative Medicine up 7.4% and MedTech up 4.6%, reflecting broad-based momentum.
  • Oncology led with 18% growth in DARZALEX and FDA approvals for TECVAYLI and CARVYKTI, expanding pipeline impact.
  • Immunology sales surged 64%, driven by TREMFYA, and FDA approval of ICOTYDE positions the company for significant market share in immunology.
  • MedTech’s cardiovascular segment showed strength in ablation and circulatory recovery, with innovative platforms like VARIPULSE and OMNYPULSE gaining traction.
  • The company remains on track for $100 billion in 2026 revenue, with confidence in sustained double-digit growth through 2027.
📅
Loading chart...
Key Metrics
Earnings dateJuly 15, 2026
P/E26.24
EPS8.64
Book Value33.74
Price to Book6.72
Debt/Equity67.73
% Insiders0.050%
Growth
Revenue Growth0.10%
Earnings Growth-0.53%
Estimates
Forward P/E17.84
Forward EPS12.71
Target Mean Price252.96
Dividend
Dividend Yield2.29%
Annual dividends5.20 USD
Ex-Div. DateMay 26, 2026
Payout59.52%
5y avg Yield2.77%

DCF Valuation

Tweak assumptions to recompute fair value for Johnson & Johnson (JNJ)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Johnson & Johnson Logo Johnson & Johnson Analysis (JNJ)

United States Health Care Official Website Stock

Is Johnson & Johnson a good investment? Johnson & Johnson (JNJ) is currently trading at 228.92 USD. Market analysts have a consensus price target of 252.96 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 26.24. This valuation is generally in line with the broader market.

Earnings Schedule: Johnson & Johnson is expected to release its next earnings report on July 15, 2026. The market consensus estimate for Forward EPS is 12.71.

For income investors, Johnson & Johnson pays a dividend yield of 2.29%. With a payout ratio of 60%, the dividend appears sustainable.

Investor FAQ

Does Johnson & Johnson pay a dividend?

Yes, it pays an annual dividend of 5.20 USD (2.29% yield).

What asset class is Johnson & Johnson?

Johnson & Johnson is classified as a Stock. You can compare it against 14 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be July 15, 2026. The company currently has a trailing EPS of 8.64.

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Exchange Ticker
BUE (Argentina) DJNJ2.BA
GER (Germany) JNJ.DE
BUE (Argentina) DJNJ3.BA
SGO (Chile) JNJ.SN
BUE (Argentina) JNJC.BA
SGO (Chile) JNJCL.SN
BUE (Argentina) JNJD.BA
MEX (Mexico) JNJ.MX
STU (Germany) JNJ.SG
BUE (Argentina) JNJ.BA
NYQ (United States) JNJ
FRA (Germany) JNJ.F
VIE (Austria) JNJ.VI
SAO (Brazil) JNJB34.SA
Dividend Yield

2.29% (5y avg: 2.77%)

Annual Dividends

5.20 USD

Next ex. div date

May 26, 2026

Payout Ratio

59.52%

Historical Dividends
Year Total Dividends
2027 1.38 USD
2026 5.38 USD
2025 5.14 USD
2024 4.91 USD
2023 4.70 USD
2022 4.45 USD
2021 4.19 USD
2020 3.98 USD
2019 3.75 USD
2018 3.54 USD
2017 3.32 USD
2016 3.15 USD
2015 2.95 USD
2014 2.76 USD
2013 2.59 USD
2012 2.40 USD
2011 2.25 USD
2010 2.11 USD
2009 1.93 USD
2008 1.80 USD
2007 1.62 USD
2006 1.46 USD
2005 1.28 USD
2004 1.10 USD
2003 0.92 USD
2002 0.79 USD
2001 1.04 USD
2000 1.24 USD
1999 1.09 USD
1998 0.97 USD
1997 0.85 USD
1996 1.09 USD
1995 1.28 USD
1994 1.13 USD
1993 1.01 USD
1992 1.32 USD
1991 1.54 USD
1990 1.31 USD
1989 1.37 USD
1988 1.92 USD
1987 1.61 USD
1986 1.37 USD
1985 1.28 USD
1984 1.17 USD
1983 1.08 USD
1982 0.97 USD
1981 1.23 USD
1980 2.22 USD
1979 2.00 USD
1978 1.70 USD
1977 1.40 USD
1976 1.05 USD
1975 0.85 USD
1974 0.73 USD
1973 0.53 USD
1972 0.45 USD
1971 0.43 USD
1970 0.54 USD
1969 0.01 USD
1968 0.00 USD
1967 0.00 USD
1966 0.00 USD
1965 0.00 USD
1964 0.00 USD
1963 0.00 USD
1962 0.00 USD

Yearly aggregated dividends

Dividends

Johnson & Johnson
Jun 09, 2026 Upcoming
Dividend
1.34 USD
Johnson & Johnson
Mar 10, 2026 Paid
Dividend
1.3 USD
Johnson & Johnson
Dec 09, 2025 Paid
Dividend
1.3 USD
Johnson & Johnson
Sep 09, 2025 Paid
Dividend
1.3 USD
Johnson & Johnson
Jun 10, 2025 Paid
Dividend
1.3 USD

Historical Split Corporate Actions

Split Date Split Ratio to 1
June 13, 2001 2.000000
June 12, 1996 2.000000
June 10, 1992 2.000000
May 11, 1989 2.000000
May 19, 1981 3.000000
May 18, 1970 3.000000
June 19, 1967 3.000000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion